STAAR Surgical Company
STAAR Surgical Company (Nasdaq: STAA) designs, develops, manufactures, and sells implantable lenses and delivery systems used in ophthalmic surgery. Its business is focused almost entirely on Implantable Collamer Lenses (ICLs), foldable lenses made from its proprietary Collamer material and implanted without removing… From the company’s description.
Over the twelve months to Oct 2, 2026, STAAR Surgical Company reported revenue of $328.27M, up 42.4% from a year earlier, and net income of $0.53M. Its operating margin was 0.2%, and operations generated $21.40M in cash. In fiscal 2025, it reported revenue of $239.44M, down 23.7% from fiscal 2024, and a net loss of $80.45M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What STAAR Surgical Company does
In the company’s own words
STAAR Surgical Company (Nasdaq: STAA) designs, develops, manufactures, and sells implantable lenses and delivery systems used in ophthalmic surgery. Its business is focused almost entirely on Implantable Collamer Lenses (ICLs), foldable lenses made from its proprietary Collamer material and implanted without removing the eye’s natural lens. The lenses treat refractive conditions including nearsightedness, farsightedness, astigmatism, and presbyopia. The product portfolio includes the EVO family—EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva—as well as Visian ICL for hyperopia. Ophthalmologists are the primary users, while customers include surgeons, vision and surgical centers, hospitals, government facilities, and distributors; products are sold in more than 85 countries. STAAR reports one operating segment, ophthalmic surgical products, and ICLs account for approximately 100% of net sales. For fiscal 2025, 91% of reported worldwide revenue came from outside the United States. The company has focused its business on ICLs and phased out its cataract lens products. Its website is www.staar.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- MONROVIA, CA
- Fiscal year end
- January
- CIK
- 718937
- SIC
- 3851
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns STAAR Surgical Company — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · STAAR Surgical Company’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do STAAR Surgical Company and its peers compare on margins and cash generation over ten years?”
- “Where did five years of STAAR Surgical Company's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in STAAR Surgical Company's last four quarterly filings that the numbers alone won't show?”